Atara Biotherapeutics Inc represents values such as innovation, scientific excellence, and patient-centricity. With a focus on developing transformative therapies for patients with serious medical conditions, Atara Biotherapeutics Inc aims to improve and extend lives. The company's corporate philosophy revolves around collaboration, dedication to research and development, and a commitment to delivering safe and effective treatments. Atara Biotherapeutics Inc continuously strives to address unmet medical needs and make a positive impact in the field of biopharmaceuticals, utilizing cutting-edge technologies and expertise to bring potential breakthroughs to patients in need.

Atara Biotherapeutics Inc is primarily present in the United States.

Atara Biotherapeutics Inc has achieved significant milestones since its establishment. Some notable achievements include the successful development and clinical progress of its innovative therapies for patients with serious diseases. The company has also made remarkable advancements in its pipeline, with the approval of certain products by regulatory authorities. Moreover, Atara Biotherapeutics Inc has entered into strategic collaborations and partnerships, strengthening its position in the biopharmaceutical industry. These achievements demonstrate the company's dedication to making breakthrough discoveries and providing effective treatments for patients in need. Atara Biotherapeutics Inc continues to strive for further milestones and growth in its pursuit of improving healthcare outcomes.

Atara Biotherapeutics Inc is a biotechnology company specializing in developing novel therapies for patients with serious medical conditions. Established in 2012, the company is headquartered in South San Francisco, California. Atara Biotherapeutics Inc focuses on developing off-the-shelf T-cell immunotherapies with the potential to target multiple diseases. By harnessing the power of the immune system, the company aims to provide innovative treatment options for cancer and autoimmune diseases. Atara's robust portfolio includes both clinical and preclinical stage therapies, which are designed to address the unmet medical needs of patients worldwide. With a dedicated team of scientists and researchers, Atara Biotherapeutics Inc continues to advance its mission of transforming medical care through groundbreaking biotechnology.

The main competitors of Atara Biotherapeutics Inc in the market are companies such as Novartis International AG, Gilead Sciences Inc, and Kite Pharma Inc.

Atara Biotherapeutics Inc is primarily active in the biotechnology industry.

Atara Biotherapeutics Inc. operates under a business model focused on developing and commercializing transformative therapies for patients with serious medical conditions. With a strong emphasis on targeted immunotherapies, the company utilizes its proprietary cell therapy platforms to create innovative treatments that harness the immune system's ability to fight diseases. Atara Biotherapeutics aims to address the unmet medical needs of patients through the development of novel therapies that target specific antigens associated with various diseases, including cancer, autoimmune disorders, and viral infections. By leveraging advanced scientific technologies, Atara Biotherapeutics Inc. strives to improve patient outcomes and quality of life.

P/E odnos Atara Biotherapeutics iznosi -0,36.

KUV kompanije Atara Biotherapeutics iznosi 0,27.

AlleAktien kvalitativni skor za Atara Biotherapeutics je 5/10.

očekivana Atara Biotherapeutics promet je 112,10 mil. USD.

Dobit očekivana Atara Biotherapeutics je -84,65 mil. USD.

Atara Biotherapeutics Inc is a US biotechnology company specializing in the development of immunotherapies for rare diseases. The company was founded in 2012 and is headquartered in South San Francisco, California. Atara Biotherapeutics' business model is focused on the development and commercialization of immunotherapies for rare diseases. The company has focused on two main areas: cancer and virus-related immune disorders. In the field of cancer, Atara Biotherapeutics has developed several immuno-oncology therapies aimed at stimulating the body's immune system to attack and destroy tumor cells. An example is Tabelecleucel (tab-cel®), an immunotherapy used to treat EBV-associated post-transplant lymphoproliferative disorder (PTLD) and EBV-associated hemophagocytic lymphohistiocytosis (HLH). The company is also working on CAR-T cell therapies for cancer treatment. In the field of virus-related immune disorders, Atara Biotherapeutics has developed therapies for diseases such as cytomegalovirus (CMV). The company has also developed an immunotherapy called Pooled Normal Human Immunoglobulin (IVIG), used to treat primary immune deficiency disorder (PIDD), a rare immune system disorder. The company is also working on the development of therapies for the treatment of COVID-19. Atara Biotherapeutics pursues an extensive research and development program focused on discovering new therapies for rare diseases. The company collaborates with leading experts in the field of immunotherapy to develop innovative new approaches to disease treatment. The company has also formed partnerships with leading pharmaceutical and biotech companies to accelerate its research and development programs and bring its products to new markets. Atara Biotherapeutics also works closely with patient organizations and regulatory agencies to better understand the needs and desires of patients and ensure that all products meet the highest safety and quality standards. Overall, Atara Biotherapeutics' business model aims to develop and commercialize new therapies for rare diseases that have not been adequately treated in the past. The company relies on close collaboration with leading experts, patient organizations, regulatory agencies, and other companies to develop innovative new approaches to disease treatment and establish worldwide leadership positions.

Atara Biotherapeutics isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Atara Biotherapeutics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Atara Biotherapeutics je US0465131078.

WKN od Atara Biotherapeutics je A1166A.

Oznaka za praćenje akcija kompanije Atara Biotherapeutics je ATRA.

U poslednjih 12 meseci, Atara Biotherapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Atara Biotherapeutics će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Atara Biotherapeutics trenutno iznosi .

Atara Biotherapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Atara Biotherapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Atara Biotherapeutics se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Atara Biotherapeutics od 23. 8. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 23. 8. 2024..

Isplata poslednje dividende izvršena je 23. 8. 2024..

U godini 2023 kompanija Atara Biotherapeutics je isplatila 0 USD kao dividende.

Dividende od Atara Biotherapeutics se isplaćuju u USD.